Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Jul 04 2024

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received tentative approval from the USFDA for Azilsartan Medoxomil Tablets. The tablets are indicated for treating hypertension and will be manufactured in Ahmedabad. The press release provides details about the approval and the drug's market potential in the United States.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated July 04, 2024, titled "Zydus receives tentative approval from USFDA for Azilsartan Medoxomil Tablets, 40 mg and 80 mg".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases